The present study found that low basal IGF-1 levels were associated with advanced HCC, such as multiple tumors and advanced stage, and low IGF-1 levels predicted shorter TTP and OS in patients treated with TACE. This evidence concerns the gene IGF1 and hepatocellular carcinoma.